title: Guidelines on the use of extracorporeal photopheresis.
abstract: BACKGROUND
  After the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma was published in 1983 with its subsequent recognition by the FDA for its refractory forms, the technology has shown significant promise in the treatment of other severe and refractory conditions in a multi-disciplinary setting. Among the major studied conditions are graft versus host disease after allogeneic bone marrow transplantation, systemic sclerosis, solid organ transplant rejection and inflammatory bowel disease.
  
  
  METHODS
  In order to provide recognized expert practical guidelines for the use of this technology for all indications the European Dermatology Forum (EDF) proceeded to address these questions in the hands of the recognized experts within and outside the field of dermatology. This was done using the recognized and approved guidelines of EDF for this task.
  
  
  CONCLUSIONS
  These guidelines provide at present the most comprehensive available expert recommendations for the use of extracorporeal photopheresis based on the available published literature and expert consensus opinion.
authors.affiliation: Department of Dermatology, Medical University of Vienna, Vienna, Austria.
authors.forename: R
authors.initials: R
authors.lastname: Knobler
authors.forename: G
authors.initials: G
authors.lastname: Berlin
authors.forename: P
authors.initials: P
authors.lastname: Calzavara-Pinton
authors.forename: H
authors.initials: H
authors.lastname: Greinix
authors.forename: P
authors.initials: P
authors.lastname: Jaksch
authors.forename: L
authors.initials: L
authors.lastname: Laroche
authors.forename: J
authors.initials: J
authors.lastname: Ludvigsson
authors.forename: P
authors.initials: P
authors.lastname: Quaglino
authors.forename: W
authors.initials: W
authors.lastname: Reinisch
authors.forename: J
authors.initials: J
authors.lastname: Scarisbrick
authors.forename: T
authors.initials: T
authors.lastname: Schwarz
authors.forename: P
authors.initials: P
authors.lastname: Wolf
authors.forename: P
authors.initials: P
authors.lastname: Arenberger
authors.forename: C
authors.initials: C
authors.lastname: Assaf
authors.forename: M
authors.initials: M
authors.lastname: Bagot
authors.forename: M
authors.initials: M
authors.lastname: Barr
authors.forename: A
authors.initials: A
authors.lastname: Bohbot
authors.forename: L
authors.initials: L
authors.lastname: Bruckner-Tuderman
authors.forename: B
authors.initials: B
authors.lastname: Dreno
authors.forename: A
authors.initials: A
authors.lastname: Enk
authors.forename: L
authors.initials: L
authors.lastname: French
authors.forename: R
authors.initials: R
authors.lastname: Gniadecki
authors.forename: H
authors.initials: H
authors.lastname: Gollnick
authors.forename: M
authors.initials: M
authors.lastname: Hertl
authors.forename: C
authors.initials: C
authors.lastname: Jantschitsch
authors.forename: A
authors.initials: A
authors.lastname: Jung
authors.forename: U
authors.initials: U
authors.lastname: Just
authors.forename: C-D
authors.initials: CD
authors.lastname: Klemke
authors.forename: U
authors.initials: U
authors.lastname: Lippert
authors.forename: T
authors.initials: T
authors.lastname: Luger
authors.forename: E
authors.initials: E
authors.lastname: Papadavid
authors.forename: H
authors.initials: H
authors.lastname: Pehamberger
authors.forename: A
authors.initials: A
authors.lastname: Ranki
authors.forename: R
authors.initials: R
authors.lastname: Stadler
authors.forename: W
authors.initials: W
authors.lastname: Sterry
authors.forename: I H
authors.initials: IH
authors.lastname: Wolf
authors.forename: M
authors.initials: M
authors.lastname: Worm
authors.forename: J
authors.initials: J
authors.lastname: Zic
authors.forename: C C
authors.initials: CC
authors.lastname: Zouboulis
authors.forename: U
authors.initials: U
authors.lastname: Hillen
mesh_terms: D001327:Autoimmune Diseases / Q000188:drug therapy*; D006084:Graft Rejection / Q000188:drug therapy; D006086:Graft vs Host Disease / Q000188:drug therapy; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D017893:Photopheresis / Q000379:methods / Q000706:statistics & numerical data*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D012595:Scleroderma, Systemic / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D017319:Photosensitizing Agents